How Drug Effects Are Assessed In Renally Impaired Patients Could Be Headed For A Change
Executive Summary
US FDA advisory committee finds merit in each of four industry-suggested alternative approaches to the current paradigm for assessing the impact of renal impairment on drug exposures; agency's own 2010 draft guidance does not reflect its current thinking on the design of dedicated pharmacokinetic studies.